Shares of Cara Therapeutics were up in trading after the company struck a licensing agreement worth up to $290 million with Switzerland’s Vifor Pharma for the commercialization of a treatment for severe itching associated with chronic kidney disease.
Aptinyx Jumps Following Positive Phase II PTSD Study Results Published: Oct. 20, 2020 By Alex Keown BioSpace Shares of Aptinyx skyrocketed more than 75% after the company reported its […]
Pfizer Inc. and BioNTech SE announced the start in Japan of combined Phase I and Phase II clinical trials of their mRNA vaccine candidate against the novel coronavirus.
Premiums for an average health insurance plan under the Affordable Care Act dropped by 2% for the 2021 coverage year, according to a report released by the Trump administration, which is seeking to invalidate the 2010 healthcare law.
Full-service health and wellness marketing agency Fingerpaint named industry veteran Danielle Bedard to the newly created role of director, corporate communications and business development.
Fingerpaint, a full-service health and wellness marketing agency with five offices across the United States and more than $80 million in revenue, named experienced bicoastal recruiter Krystal Gomola as lead recruiter.
Catalyst Pharmaceuticals filed new patent infringement lawsuits against Jacobus Pharmaceuticals and PANTHERx Rare LLC over a treatment for the rare autoimmune disease Lambert-Eaton Myasthenic Syndrome (LEMS).
German biotech company Evotec said on Monday the company had received a grant from the Bill & Melinda Gates Foundation to help identify and develop potential monoclonal antibody (mAbS) drugs for the prevention of severe Covid-19.
UCB is investing more than £1 billion ($1.29 billion) over five years to expand the company’s research and development capabilities in the U.K., which will include a transition to a newly acquired 47-acre R&D campus from Eli Lilly located in Windlesham, Surrey.
Galapagos and Servier reported that their ROCELLA Phase II clinical trial of GLPG1972/S201086 failed to meet the study’s primary endpoint in osteoarthritis knee repair.
